{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T09:58:01Z","timestamp":1780567081716,"version":"3.54.1"},"reference-count":52,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012224","name":"Xuzhou University of Technology","doi-asserted-by":"publisher","award":["KC23152"],"award-info":[{"award-number":["KC23152"]}],"id":[{"id":"10.13039\/501100012224","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005145","name":"Basic Research Program of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20231166"],"award-info":[{"award-number":["BK20231166"]}],"id":[{"id":"10.13039\/501100005145","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012217","name":"Xuzhou Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012217","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Cell Research"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.yexcr.2025.114495","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T19:06:55Z","timestamp":1741115215000},"page":"114495","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Protocadherin 17 weakens the lenvatinib resistance of liver cancer through inducing ferroptosis"],"prefix":"10.1016","volume":"447","author":[{"given":"Jun","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guowei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxuan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengliang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3278-2679","authenticated-orcid":false,"given":"Dechun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yexcr.2025.114495_bib1","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1097\/SLA.0000000000000710","article-title":"Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis","volume":"261","author":"Tabrizian","year":"2015","journal-title":"Ann. Surg."},{"key":"10.1016\/j.yexcr.2025.114495_bib2","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.cgh.2023.01.039","article-title":"Breakthroughs in hepatocellular carcinoma therapies","volume":"21","author":"Singal","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.yexcr.2025.114495_bib3","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41392-020-00264-x","article-title":"Targeted therapy for hepatocellular carcinoma","volume":"5","author":"Huang","year":"2020","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.yexcr.2025.114495_bib4","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1002\/hep.32740","article-title":"The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma","volume":"77","author":"Donne","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.yexcr.2025.114495_bib5","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.2217\/fon-2017-0689","article-title":"Lenvatinib and its use in the treatment of unresectable hepatocellular carcinoma","volume":"14","author":"Baxter","year":"2018","journal-title":"Future Oncol."},{"key":"10.1016\/j.yexcr.2025.114495_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13246310","article-title":"Is there still a place for tyrosine kinase inhibitors for the treatment of hepatocellular carcinoma at the time of immunotherapies? A focus on lenvatinib","volume":"13","author":"Decraecker","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.yexcr.2025.114495_bib7","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yexcr.2025.114495_bib8","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.yexcr.2025.114495_bib9","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial","volume":"16","author":"Motzer","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.yexcr.2025.114495_bib10","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1002\/hep.31921","article-title":"Lenvatinib targets FGF receptor 4 to enhance antitumor immune response of anti-programmed cell death-1 in HCC","volume":"74","author":"Yi","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.yexcr.2025.114495_bib11","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1158\/0008-5472.CAN-22-0963","article-title":"METTL1-Mediated m7G tRNA modification promotes lenvatinib resistance in hepatocellular carcinoma","volume":"83","author":"Huang","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.yexcr.2025.114495_bib12","article-title":"Lenvatinib for hepatocellular carcinoma: from preclinical mechanisms to anti-cancer therapy","volume":"1874","author":"Zhao","year":"2020","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.yexcr.2025.114495_bib13","article-title":"Efficacy and safety of transarterial chemoembolization plus lenvatinib in the treatment of advanced hepatocellular carcinoma: a meta-analysis","volume":"102","author":"Li","year":"2023","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.yexcr.2025.114495_bib14","doi-asserted-by":"crossref","first-page":"865","DOI":"10.2174\/1568009622666220428111327","article-title":"Resistance of lenvatinib in hepatocellular carcinoma","volume":"22","author":"Guo","year":"2022","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.yexcr.2025.114495_bib15","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/mc.23625","article-title":"The action and resistance mechanisms of Lenvatinib in liver cancer","volume":"62","author":"Buttell","year":"2023","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.yexcr.2025.114495_bib16","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1111\/cas.15378","article-title":"Ferroptosis is induced by lenvatinib through fibroblast growth factor receptor-4 inhibition in hepatocellular carcinoma","volume":"113","author":"Iseda","year":"2022","journal-title":"Cancer Sci."},{"key":"10.1016\/j.yexcr.2025.114495_bib17","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","article-title":"Ferroptosis: mechanisms, biology and role in disease","volume":"22","author":"Jiang","year":"2021","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.yexcr.2025.114495_bib18","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41392-022-01046-3","article-title":"Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy","volume":"7","author":"Gao","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.yexcr.2025.114495_bib19","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jhep.2022.01.009","article-title":"COMMD10 inhibits HIF1alpha\/CP loop to enhance ferroptosis and radiosensitivity by disrupting Cu-Fe balance in hepatocellular carcinoma","volume":"76","author":"Yang","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.yexcr.2025.114495_bib20","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1038\/s41388-022-02370-2","article-title":"PCDHB14 promotes ferroptosis and is a novel tumor suppressor in hepatocellular carcinoma","volume":"41","author":"Liu","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.yexcr.2025.114495_bib21","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114351","article-title":"YAP\/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis","volume":"13","author":"Gao","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.yexcr.2025.114495_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2022.109216","article-title":"FAM98A promotes resistance to 5-fluorouracil in colorectal cancer by suppressing ferroptosis","volume":"722","author":"He","year":"2022","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.yexcr.2025.114495_bib23","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1158\/1541-7786.MCR-22-0085","article-title":"Ceramide kinase inhibition drives ferroptosis and sensitivity to Cisplatin in mutant KRAS lung cancer by dysregulating VDAC-mediated mitochondria function","volume":"20","author":"Vu","year":"2022","journal-title":"Mol. Cancer Res. : MCR"},{"key":"10.1016\/j.yexcr.2025.114495_bib24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12943-022-01530-y","article-title":"Ferroptosis in cancer therapy: a novel approach to reversing drug resistance","volume":"21","author":"Zhang","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.yexcr.2025.114495_bib25","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4161\/cam.5.2.14374","article-title":"Non-clustered protocadherin","volume":"5","author":"Kim","year":"2011","journal-title":"Cell Adhes. Migrat."},{"key":"10.1016\/j.yexcr.2025.114495_bib26","doi-asserted-by":"crossref","first-page":"51720","DOI":"10.18632\/oncotarget.10102","article-title":"Protocadherin 17 functions as a tumor suppressor suppressing Wnt\/\u03b2-catenin signaling and cell metastasis and is frequently methylated in breast cancer","volume":"7","author":"Yin","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.yexcr.2025.114495_bib27","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/mc.22808","article-title":"Recurrent transcriptional loss of the PCDH17 tumor suppressor in laryngeal squamous cell carcinoma is partially mediated by aberrant promoter DNA methylation","volume":"57","author":"Byzia","year":"2018","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.yexcr.2025.114495_bib28","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/path.4093","article-title":"Protocadherin 17 acts as a tumour suppressor inducing tumour cell apoptosis and autophagy, and is frequently methylated in gastric and colorectal cancers","volume":"229","author":"Hu","year":"2013","journal-title":"J. Pathol."},{"key":"10.1016\/j.yexcr.2025.114495_bib29","article-title":"Ubiquitin ligase NEDD4 promotes the proliferation of hepatocellular carcinoma cells through targeting PCDH17 protein for ubiquitination and degradation","volume":"300","author":"Liu","year":"2024","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.yexcr.2025.114495_bib30","article-title":"Deciphering the oncogenic potential of ADAM9 in hepatocellular carcinoma through bioinformatics and experimental approaches","volume":"14","author":"Jiang","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.yexcr.2025.114495_bib31","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13062-024-00572-0","article-title":"MLL1 promotes placental trophoblast ferroptosis and aggravates preeclampsia symptoms through epigenetic regulation of RBM15\/TRIM72\/ADAM9 axis","volume":"19","author":"Li","year":"2024","journal-title":"Biol. Direct"},{"key":"10.1016\/j.yexcr.2025.114495_bib32","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-019-0087-0","article-title":"PCDH17 increases the sensitivity of colorectal cancer to 5-fluorouracil treatment by inducing apoptosis and autophagic cell death","volume":"4","author":"Liu","year":"2019","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.yexcr.2025.114495_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10061304","article-title":"First-line targeted therapy for hepatocellular carcinoma: role of Atezolizumab\/Bevacizumab combination","volume":"10","author":"Tella","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.yexcr.2025.114495_bib34","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/ajhp\/zxaa365","article-title":"Systemic targeted and immunotherapy for advanced hepatocellular carcinoma","volume":"78","author":"Cersosimo","year":"2021","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.yexcr.2025.114495_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbrc.2019.02.015","article-title":"Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades","volume":"513","author":"Hoshi","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.yexcr.2025.114495_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23084408","article-title":"Synergistic anti-Angiogenic effect of combined VEGFR kinase inhibitors, lenvatinib, and regorafenib: a therapeutic potential for breast cancer","volume":"23","author":"Bajbouj","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yexcr.2025.114495_bib37","article-title":"Role of endothelin ET(A) receptors in the hypertension induced by the VEGFR-2 kinase inhibitors axitinib and lenvatinib in conscious freely-moving rats","author":"Pannucci","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.yexcr.2025.114495_bib38","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1158\/0008-5472.CAN-20-2426","article-title":"Inhibition of FGFR reactivates IFN\u03b3 signaling in tumor cells to enhance the combined antitumor activity of lenvatinib with anti-PD-1 antibodies","volume":"82","author":"Adachi","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.yexcr.2025.114495_bib39","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41388-022-02551-z","article-title":"Targeting SLP2-mediated lipid metabolism reprograming restricts proliferation and metastasis of hepatocellular carcinoma and promotes sensitivity to Lenvatinib","volume":"42","author":"Liu","year":"2023","journal-title":"Oncogene"},{"key":"10.1016\/j.yexcr.2025.114495_bib40","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1452","article-title":"KDM6A promotes hepatocellular carcinoma progression and dictates lenvatinib efficacy by upregulating FGFR4 expression","volume":"13","author":"Guo","year":"2023","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.yexcr.2025.114495_bib41","first-page":"40","volume":"vol. 4","author":"Llamoza-Torres","year":"2024"},{"key":"10.1016\/j.yexcr.2025.114495_bib42","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s13046-021-02011-8","article-title":"A positive feedback loop between Periostin and TGF\u03b21 induces and maintains the stemness of hepatocellular carcinoma cells via AP-2\u03b1 activation","volume":"40","author":"Chen","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.yexcr.2025.114495_bib43","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ygyno.2021.06.032","article-title":"Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer","volume":"162","author":"Backes","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.yexcr.2025.114495_bib44","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: an iron-dependent form of nonapoptotic cell death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.yexcr.2025.114495_bib45","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1016\/j.ymthe.2021.03.022","article-title":"Emerging mechanisms and targeted therapy of ferroptosis in cancer","volume":"29","author":"Wang","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.yexcr.2025.114495_bib46","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1038\/s41401-023-01062-1","article-title":"Aspirin triggers ferroptosis in hepatocellular carcinoma cells through restricting NF-\u03baB p65-activated SLC7A11 transcription","volume":"44","author":"Wang","year":"2023","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.yexcr.2025.114495_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2022.102317","article-title":"Inhibition of STAT3-ferroptosis negative regulatory axis suppresses tumor growth and alleviates chemoresistance in gastric cancer","volume":"52","author":"Ouyang","year":"2022","journal-title":"Redox Biol."},{"key":"10.1016\/j.yexcr.2025.114495_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113150","article-title":"Artesunate inhibits growth of sunitinib-resistant renal cell carcinoma cells through cell cycle arrest and induction of ferroptosis","volume":"12","author":"Markowitsch","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.yexcr.2025.114495_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.122411","article-title":"Regulatory network of ferroptosis and autophagy by targeting oxidative stress defense using sulfasalazine in triple-negative breast cancer","volume":"339","author":"Takatani-Nakase","year":"2024","journal-title":"Life Sci."},{"key":"10.1016\/j.yexcr.2025.114495_bib50","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3233\/CBM-181493","article-title":"Aberrant methylation of PCDH17 gene in high-grade serous ovarian carcinoma","volume":"23","author":"Baranova","year":"2018","journal-title":"Cancer Biomarkers : section A of Disease markers"},{"key":"10.1016\/j.yexcr.2025.114495_bib51","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/s41419-019-2064-5","article-title":"ROS-mediated autophagy increases intracellular iron levels and ferroptosis by ferritin and transferrin receptor regulation","volume":"10","author":"Park","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.yexcr.2025.114495_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24010449","article-title":"Lipid peroxidation and iron metabolism: two corner stones in the homeostasis control of ferroptosis","volume":"24","author":"Rochette","year":"2022","journal-title":"Int. J. Mol. Sci."}],"container-title":["Experimental Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482725000916?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482725000916?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T05:23:18Z","timestamp":1762147398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014482725000916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0014482725000916"],"URL":"https:\/\/doi.org\/10.1016\/j.yexcr.2025.114495","relation":{},"ISSN":["0014-4827"],"issn-type":[{"value":"0014-4827","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Protocadherin 17 weakens the lenvatinib resistance of liver cancer through inducing ferroptosis","name":"articletitle","label":"Article Title"},{"value":"Experimental Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexcr.2025.114495","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"114495"}}